Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients

Figure 3 Tolvaptan does not affective liver function. A: Tolvaptan (15 mg/d for 5-14 d) does not affective liver function [model for end-stage liver disease (MELD) score, alanine aminotransferase (ALT) and aspartate aminotransferase (AST)] in patients with preexisting liver cirrhosis (P > 0.05); B: Kaplan-Meier analysis of the 1-mo survival of patients without hyponatremia, as well as with and without short-term correction of hyponatremia, did not show any significant difference between patient groups.